Yes, tirzepatide can be used for weight loss and glucose control in patients with type 2 diabetes, though your starting dose and escalation timeline may differ from non-diabetic patients
Consequently, this is not a good form of B12 to use
For deeper background, see GLP 1 Drugs and GLP 1 Receptor Agonist
Clinical studies show Wegovy typically produces greater weight loss, with patients losing an average of 15-20% of their body weight compared to Saxendas 5-10%
Dibutyryl-cGMP, a synthetic cGMP derivative, reduces ionomycin-stimulated eryptosis [170]
Currently, at least 10 states have listed Wegovy as a preferred drug in their formulary: California Delaware Massachusetts Michigan Minnesota Mississippi New Hampshire Pennsylvania Rhode Island Virginia Some states may require prior authorization for Wegovy or may have certain quantity or coverage limitations